أعضاء هيئة التدريس

• Personalized/Precision Oncology
• Multi-omics
• Novel Biomarkers and Drug Targets
• Breast Cancer

• Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications. Nature Communications. 2022; 13, 946. https://doi.org/10.1038/s41467-022-28639-4 https://www.nature.com/articles/s41467-022-28639-4

• Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer. NPJ Breast Cancer. 2022;8(1):57. https://doi.org/10.1038/s41523-022-00425-x https://pubmed.ncbi.nlm.nih.gov/35501337/

• G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma. Clin Cancer Res. 2021;27(9):2624-2635. https://doi.org/10.1158/1078-0432.CCR-20-3463https://pubmed.ncbi.nlm.nih.gov/33589432/

• A short ERK5 isoform modulates nucleocytoplasmic shuttling of active ERK5 and associates with poor survival in breast cancer. bioRxiv 2021.03.23.436061; https://doi.org/10.1101/2021.03.23.436061 https://www.biorxiv.org/content/10.1101/2021.03.23.436061v1.abstract

• G9a-mediated repression of CDH10 in hypoxia enhances breast tumour cell motility and associates with poor survival outcome. Theranostics. 2020;10(10):4515-4529. Published 2020 Mar 15. https://doi.org/10.7150/thno.41453 https://pubmed.ncbi.nlm.nih.gov/32292512/

• Differential gene expression of tumor-infiltrating CD8+ T cells in advanced versus early-stage colorectal cancer and identification of a gene signature of poor prognosis. J Immunother Cancer. 2020;8(2):e001294. https://doi.org/10.1136/jitc-2020-001294 https://pubmed.ncbi.nlm.nih.gov/32948653/

• Differential gene expression of tumor-infiltrating CD4+ T cells in advanced versus early stage colorectal cancer and identification of a gene signature of poor prognosis. Oncoimmunology. 2020;9(1):1825178. Published 2020 Sep 30. https://doi.org/10.1080/2162402X.2020.1825178 https://pubmed.ncbi.nlm.nih.gov/33101776/

• Clinicopathologic significance of nuclear HER4 and phospho-YAP(S127) in human breast cancers and matching brain metastases. Ther Adv Med Oncol. 2020;12:1758835920946259. https://doi.org/10.1177/1758835920946259 https://pubmed.ncbi.nlm.nih.gov/33014146/

• Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019;10(1):1741. https://www.ncbi.nlm.nih.gov/pubmed/30988301

• Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer. JCI Insight, 2019;5. pii: 124092. https://www.ncbi.nlm.nih.gov/pubmed/30830863

• EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma. Cancers (Basel), 2018 ;10(12). pii: E519. https://www.ncbi.nlm.nih.gov/pubmed/30562956

• A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics, 2018; 50(7):968-978. https://www.ncbi.nlm.nih.gov/pubmed/29915430

• Characterization of a novel breast cancer cell line derived from a metastatic bone lesion of a breast cancer patient. Breast Cancer Res Treat, 2018;170(1):179-188. https://www.ncbi.nlm.nih.gov/pubmed/29468485

• Multidimensional phenotyping of breast cancer cell lines to guide preclinical research. Breast Cancer Res Treat, 2018;167(1):289-301. https://www.ncbi.nlm.nih.gov/pubmed/28889351

• Long Noncoding RNAs CUPID1 and CUPID2 Mediate Breast Cancer Risk at 11q13 by Modulating the Response to DNA Damage. American Journal of Human Genetics, 2017;101(2):255-266. https://www.ncbi.nlm.nih.gov/pubmed/28777932

• RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy. Oncotarget, 2016, 13;7(37):60087-60100. https://www.ncbi.nlm.nih.gov/pubmed/27507046

• Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer. Oncogenesis, 2014;3:e100. https://www.ncbi.nlm.nih.gov/pubmed/24752235

• Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma. Clinical Cancer Research, 2014;20(12):3187-97. https://www.ncbi.nlm.nih.gov/pubmed/24838526

• Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer. Oncotarget, 2014;5(10):3145-58. https://www.ncbi.nlm.nih.gov/pubmed/24762669

• Postchemotherapy and tumor-selective targeting with the La-specific DAB4 monoclonal antibody relates to apoptotic cell clearance. Journal of Nuclear Medicine, 2014;55(5):772-9. https://www.ncbi.nlm.nih.gov/pubmed/24676755

• Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor. Journal of Nuclear Medicine, 2013;54(6):913-21. https://www.ncbi.nlm.nih.gov/pubmed/23564760

• All publications at https://www.ncbi.nlm.nih.gov/pubmed/?term=al-ejeh

• 2016 - Certificate of Excellence in Reviewing, Oncology Reports Journal - Spandidos Publications (Athens/Greece)
• 2016 - Commendation Letter for Outstanding Contribution to Institutional Animal Ethics Committee, QIMRB Medical Research Institute (Brisbane, Australia)
• 2016 - Outstanding External Assessor Contribution to NH&MRC Honour Roll 2016, Australian National Health & Medical Research Council (Canberra, Australia)
• 2014 - Commendation Letter for insightful oral presentation as a keynote speaker at the Australian and New Zealand Society of Nuclear Medicine, Australian and New Zealand Society of Nuclear Medicine (ANZSNM, Australia)
• 2008 - Asia-Pacific Frost & Sullivan Technology Innovation Award For APOMAB innovation in Oncaidia Ltd., Frost & Sullivan (Santa Clara, California)
• 2003 - ASMR Young Investigator Award, Australian Society for Medical Research (ASMR, Australia)